Theralase® Provides Update on Phase II Bladder Cancer Clinical Study
Go back to Theralase® Provides Update on Phase II Bladder Cancer Clinical Study| ISHARES 20+ YEAR TREASURY BOND ETF (NASDAQ: TLT) | Delayed: 86.27 +0.18 (0.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $86.09 | 52 Week High | $143.62 | |||
| Open | $86.12 | 52 Week Low | $118.66 | |||
| Day High | $86.39 | P/E | N/A | |||
| Day Low | $86.11 | EPS | $0.00 | |||
| Volume | 5,234,918 | |||||
| Theralase Technologies Inc Ordinary Share (AMEX: TLTFF) | Delayed: 0.17 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.17 | 52 Week High | $0.35 | |||
| Open | $0.17 | 52 Week Low | $0.18 | |||
| Day High | $0.17 | P/E | N/A | |||
| Day Low | $0.17 | EPS | $0.00 | |||
| Volume | 37,000 | |||||
